Related Experiment Videos
Current Status of Dendritic Cell-Based Tumor Vaccination
J. Dannull1, T. Cerny, D.K. Ackermann
1Laborforschungsabteilung, Kantonsspital St. Gallen, St. Gallen.
Abstract:
For several decades, approaches utilizing nonspecific immune stimulants have provided evidence that the immune system, when properly activated, may eradicate cancer cells. However, it was only after the identification of the first human tumor-associated antigen, less than a decade ago, that development of specific vaccination procedures for cancer patients became feasible. Recent insights into the pivotal role of dendritic cells (DCs) for initiation and regulation of immune responses have allowed the design of DC-based tumor vaccination trials. In addition, the development of methods to raise large numbers of DCs from peripheral blood monocytes has paved the way for their clinical application. Tumor-specific vaccination utilizing antigen-loaded autologous DCs, has become practical and applicable to patients and may lead to vigorous antitumor responses. This review outlines recent progress, obstacles still to be overcome, and the future potential of DC-based vaccination. Copyright 2000 S. Karger GmbH, Freiburg
Insights
Cancer immunotherapy has advanced with tumor-associated antigens and dendritic cell (DC) vaccines. Antigen-loaded autologous DCs offer a practical approach for robust antitumor responses in patients.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Nonspecific immune stimulants have shown potential in eradicating cancer cells.
- Identification of tumor-associated antigens enabled specific cancer vaccination.
- Dendritic cells (DCs) play a crucial role in initiating and regulating immune responses.
Purpose of the Study:
- To review the progress, challenges, and future potential of dendritic cell-based tumor vaccination.
- To highlight the feasibility of DC-based vaccination following recent scientific insights.
Main Methods:
- Development of methods to generate large numbers of DCs from peripheral blood monocytes.
- Utilizing antigen-loaded autologous DCs for tumor-specific vaccination.
Main Results:
- DC-based vaccination trials have been designed based on insights into DC function.
- Methods for large-scale DC generation facilitate clinical application.
- Tumor-specific vaccination with autologous DCs is practical and may induce strong antitumor responses.
Conclusions:
- Dendritic cell-based vaccination represents a promising strategy for cancer immunotherapy.
- Further research is needed to overcome existing obstacles and maximize the potential of DC vaccination.